Brief: Polyphor: DSMB Says Phase III Balixafortide Study To Go On Without Modifications
14/12/2020 06:36
Dec 14 (Reuters) - POLYPHOR AG POLN.S :
* ANNOUNCES THIRD POSITIVE DATA SAFETY MONITORING BOARD
(DSMB)
RECOMMENDATION TO CONTINUE PHASE III BALIXAFORTIDE FORTRESS
STUDY WITHOUT MODIFICATIONS
* DSMB INDICATED THAT PHASE III CLINICAL STUDY SHOULD
CONTINUE
WITHOUT MODIFICATIONS.
Source text for Eikon: ID:nEQbBmq0ca
Further company coverage: POLN.S
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Spexis AG
See all newsBrief: Spexis AG: Expects Audit Of 2023 Financials Will Not Be Completed By 31 July 2024
Brief: Spexis Launches Appeal Against Six Exchange Regulation Decision To Suspend Trading Of Its Shares.
Brief: Spexis AG- Audit Costs Have Not Been Approved Yet And Further Extension May Be Required
Brief: Spexis Announces CFO Hernan Levett Has Decided To Pursue New Career Outside Company
Brief: Spexis: Total Loss Of CHF 3.9 Mln In H1 2023